+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Small Molecule Multi-target Angiogenesis Inhibitor Market - Global Forecast 2025-2030- Product Image
Small Molecule Multi-target Angiogenesis Inhibitor Market - Global Forecast 2025-2030- Product Image
Sale

Small Molecule Multi-target Angiogenesis Inhibitor Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081849
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The global small molecule multi-target angiogenesis inhibitors market is rapidly shaping oncology innovation, resulting in optimized patient care pathways and shifts in product development strategies. Pharmaceutical leaders and stakeholders are aligning resources to harness these novel therapeutics, ensuring organizational agility in a dynamic regulatory and supply landscape.

Market Snapshot: Small Molecule Multi-Target Angiogenesis Inhibitors

This market demonstrates robust growth, propelled by demand for therapies that disrupt tumor vascularization through simultaneous multi-pathway inhibition. Notable advances in clinical strategy, structure-activity relationship optimization, and adoption of predictive diagnostics are reshaping treatment paradigms. Key regions are witnessing accelerated regulatory review processes and a surge of collaborative research, enabling more rapid market entry for new agents.

Scope & Segmentation of the Angiogenesis Inhibitor Market

The report delivers comprehensive segmentation to provide stakeholders with granular analysis and actionable intelligence. Key focus areas include:

  • Indications: Breast cancer, colorectal cancer, liver cancer, lung cancers (including non-small cell and small cell types), and renal cancer.
  • Mechanism of Action Target: Inhibitors targeting fibroblast growth factor receptors, platelet-derived growth factor receptors, and vascular endothelial growth factor receptors.
  • Route of Administration: Intravenous and oral delivery pathways, each with unique clinical and operational implications.
  • End Users: Cancer clinics, hospitals, and research institutes with varying procurement requirements and reimbursement models.
  • Formulation: Capsules, injectables, and tablets supporting treatment accessibility and patient adherence.
  • Regional Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (with details across the United Kingdom, Germany, Russia, United Arab Emirates, and others), and Asia-Pacific (including China, India, Japan, Australia, and additional high-growth territories).
  • Companies Profiled: Pfizer Inc., Bayer AG, Novartis AG, Eisai Co., Ltd., Exelixis, Inc., Ipsen S.A., Merck KGaA, Astellas Pharma Inc., Boehringer Ingelheim International GmbH, and Eli Lilly and Company.

Technological advancements, such as biomarker integration and artificial intelligence-guided drug optimization, are key features analyzed within this segmentation.

Key Takeaways for Senior Decision-Makers

  • Multi-target angiogenesis inhibitors offer deeper anti-tumor responses compared to single-pathway strategies, positioning them as a critical solution for aggressive and treatment-resistant cancers.
  • Integration of predictive biomarkers and companion diagnostics enhances patient selection and drives the shift towards precision oncology, minimizing off-target effects and aligning with regulatory trends.
  • Investment in combined research platforms and strategic partnerships, including joint ventures and licensing agreements, is pivotal for pipeline development and value creation within this competitive sector.
  • Product launches are influenced by local regulatory frameworks, procurement strategies, and reimbursement environments, requiring organizations to tailor market access and commercialization pathways by region.
  • Portfolio diversification—through mergers, acquisitions, or spin-off entities—enables companies to address evolving clinical requirements and enhance portfolio resilience.

Tariff Impact on Supply Chains and Pricing

Recent United States tariff policies have introduced new supply chain risk factors, particularly due to heightened duties on active pharmaceutical ingredient imports. These policy changes have prompted manufacturers to reevaluate sourcing strategies, optimize domestic production capabilities, and implement dual-source contracts. Companies succeeding in agile customs planning and diversified manufacturing networks are best positioned to maintain stable pricing structures and ensure uninterrupted market supply against ongoing regulatory and economic fluctuations.

Methodology & Data Sources

This report synthesizes primary research from executive interviews, clinical investigator insights, and regulatory expert feedback with secondary analysis of peer-reviewed literature, patent filings, and market disclosures. Triangulation and scenario analysis were applied for data validation and to ensure robust, qualitative depth supported by external advisor reviews.

Why This Report Matters for B2B Stakeholders

  • Empowers executive teams to refine R&D pipelines, optimize clinical trial strategy, and strengthen asset positioning through in-depth market and competitor insights.
  • Supports informed investment and procurement decisions by delivering region-specific regulatory, reimbursement, and pricing analysis.
  • Guides innovation and commercialization planning with actionable segmentation and analysis of emerging technology and partnership trends.

Conclusion

Comprehensive insight into this market equips stakeholders to anticipate therapeutic advancements, regulatory shifts, and evolving commercial models. Well-prepared organizations can leverage these findings to secure leadership within the competitive angiogenesis inhibitor landscape.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of predictive biomarkers to optimize patient selection for multi-target angiogenesis therapies
5.2. Advancements in oral small molecule formulations improving bioavailability and patient adherence
5.3. Combining multi-target angiogenesis inhibitors with immune checkpoint inhibitors for enhanced efficacy
5.4. Addressing therapeutic resistance through dual inhibition of VEGFR and FGFR pathways in oncology
5.5. Emergence of real-world evidence demonstrating cost-effectiveness of multi-target angiogenesis agents
5.6. Expanding applications of multi-target angiogenesis inhibitors in ocular vascular diseases beyond cancer
5.7. AI-driven drug discovery accelerating identification of novel small molecules targeting angiogenesis pathways
5.8. Regulatory focus on safety profiles driving development of selective multi-kinase angiogenesis inhibitors
5.9. Personalized dosing strategies informed by pharmacogenomic profiling in multi-target angiogenesis therapy
5.10. Strategic partnerships between biotech and Big Pharma to accelerate multi-target angiogenesis drug development
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Small Molecule Multi-target Angiogenesis Inhibitor Market, by Indication
8.1. Introduction
8.2. Breast Cancer
8.3. Colorectal Cancer
8.4. Liver Cancer
8.5. Lung Cancer
8.5.1. Non Small Cell Lung Cancer
8.5.2. Small Cell Lung Cancer
8.6. Renal Cancer
9. Small Molecule Multi-target Angiogenesis Inhibitor Market, by Mechanism Of Action Target
9.1. Introduction
9.2. Fibroblast Growth Factor Receptor Inhibitor
9.3. Platelet Derived Growth Factor Receptor Inhibitor
9.4. Vascular Endothelial Growth Factor Receptor Inhibitor
10. Small Molecule Multi-target Angiogenesis Inhibitor Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
11. Small Molecule Multi-target Angiogenesis Inhibitor Market, by End User
11.1. Introduction
11.2. Cancer Clinics
11.3. Hospitals
11.4. Research Institutes
12. Small Molecule Multi-target Angiogenesis Inhibitor Market, by Formulation
12.1. Introduction
12.2. Capsule
12.3. Injectable
12.4. Tablet
13. Americas Small Molecule Multi-target Angiogenesis Inhibitor Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Bayer AG
16.3.3. Novartis AG
16.3.4. Eisai Co., Ltd.
16.3.5. Exelixis, Inc.
16.3.6. Ipsen S.A.
16.3.7. Merck KGaA
16.3.8. Astellas Pharma Inc.
16.3.9. Boehringer Ingelheim International GmbH
16.3.10. Eli Lilly and Company
17. Research AI18. Research Statistics19. Research Contacts20. Research Articles21. Appendix
List of Figures
FIGURE 1. SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET: RESEARCHAI
FIGURE 26. SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET: RESEARCHSTATISTICS
FIGURE 27. SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET: RESEARCHCONTACTS
FIGURE 28. SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY RENAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY RENAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR RECEPTOR INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR RECEPTOR INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY CANCER CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY CANCER CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 85. CANADA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 86. CANADA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 87. CANADA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 88. CANADA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 89. CANADA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 90. CANADA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 91. CANADA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. CANADA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. CANADA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. CANADA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. CANADA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 96. CANADA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 97. MEXICO SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. MEXICO SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. MEXICO SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 100. MEXICO SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 101. MEXICO SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 102. MEXICO SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 103. MEXICO SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. MEXICO SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. MEXICO SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. MEXICO SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. MEXICO SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 108. MEXICO SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 159. GERMANY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 160. GERMANY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 161. GERMANY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 162. GERMANY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 163. GERMANY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 164. GERMANY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 165. GERMANY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. GERMANY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. GERMANY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. GERMANY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. GERMANY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 170. GERMANY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 171. FRANCE SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 172. FRANCE SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 173. FRANCE SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 174. FRANCE SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 175. FRANCE SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 176. FRANCE SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 177. FRANCE SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. FRANCE SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. FRANCE SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. FRANCE SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. FRANCE SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 182. FRANCE SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 195. ITALY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 196. ITALY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 197. ITALY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 198. ITALY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 199. ITALY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 200. ITALY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 201. ITALY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. ITALY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. ITALY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. ITALY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. ITALY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 206. ITALY SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 207. SPAIN SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. SPAIN SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. SPAIN SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 210. SPAIN SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 211. SPAIN SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 212. SPAIN SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 213. SPAIN SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. SPAIN SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. SPAIN SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. SPAIN SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. SPAIN SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 218. SPAIN SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION TARGET, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA SMALL MOLECULE MULTI-TARGET ANGIOGENESIS INHIBITOR MARKET SIZE, BY END USER, 2025-2030 (US

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Small Molecule Multi-target Angiogenesis Inhibitor market report include:
  • Pfizer Inc.
  • Bayer AG
  • Novartis AG
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Ipsen S.A.
  • Merck KGaA
  • Astellas Pharma Inc.
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company

Related Topics

Related Reports

Macromolecular Single-target Angiogenesis Inhibitor Market - Global Forecast 2025-2030 - Product Image

Macromolecular Single-target Angiogenesis Inhibitor Market - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Complement Inhibitors Market - Global Forecast 2025-2030 - Product Image

Complement Inhibitors Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Complement Inhibitors - Pipeline Insight, 2025 - Product Image

Complement Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 150 Pages
  • Global
From
Factor XI Inhibitors - Pipeline Insight, 2025 - Product Image

Factor XI Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Complement Inhibitors Market Report 2025 - Product Image

Complement Inhibitors Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.